Canadian Patent No. 2,461,202 (the 202 Patent), which was asserted by Bristol-Myers Squibb Canada Co. and Bristol-Myers Squibb Holdings Ireland Unlimited Company (collectively, BMS). The 202 Patent claims the active ingredient apixaban and its use for the treatment and prevention of thromboembolic disorders (blood clots). Canadian Patent No. 2,791,171 (the 171 Patent), which was asserted by BMS and Pfizer Inc. (collectively, BMS & Pfizer). The 171 Patent claims tablet formulations of apixaban. The Defendants' only non-infringement allegation was that the asserted claims of each of the patents were invalid. The 202 Patent: compound and use claims valid and infringed Construction. The sole issue with respect to construction of the asserted claims of the 202 Patent was